AbbVie Stock News

Great businesses have a habit of remaining so even when market volatility arises. The stock market is cyclical, and ups as well as downs are inevitable.

Dividend Aristocrats are the top option for income driven investors.

Shares of AbbVie (ABBV -0.24%) were bouncing along merrily for most of Thursday's trading session, until news of a fresh demand from the White House quashed the rally. Initially, the market was cheered by better-than-expected quarterly results published by the company that morning.

AbbVie Inc. (NYSE:ABBV ) Q2 2025 Earnings Conference Call July 31, 2025 9:00 AM ET Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Jeffrey Ryan Stewart - Executive VP & Chief Commercial Officer Robert A. Michael - CEO & Chairman of the Board Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott T.

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House said on Thursday.

President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.

AbbVie Inc. NYSE: ABBV stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 earnings report. The biopharmaceutical giant reported global net revenue of $15.42 billion, beating expectations for $14.93 billion.

Second quarter EPS came in at $2.97 on revenue of $15.4 billion, beating analysts expectations.